| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 34.236 | 106.279 | 1.330.074 | 1.434.407 | 1.012.109 | 129.448 | 109.066 | 134 | 0 | 0 |
| Total Income - EUR | 34.828 | 112.720 | 1.334.966 | 1.445.831 | 1.021.933 | 139.755 | 118.160 | 135 | 0 | 0 |
| Total Expenses - EUR | 115.942 | 101.644 | 1.242.209 | 1.288.276 | 868.680 | 130.472 | 115.612 | 4.178 | 4.784 | 1.837 |
| Gross Profit/Loss - EUR | -81.115 | 11.076 | 92.757 | 157.555 | 153.253 | 9.283 | 2.548 | -4.043 | -4.784 | -1.837 |
| Net Profit/Loss - EUR | -81.115 | 11.076 | 77.979 | 130.621 | 131.339 | 7.101 | -502 | -4.047 | -4.784 | -1.837 |
| Employees | 1 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Grandpharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 34.485 | 17.828 | 11.905 | 66.461 | 26.420 | 14.203 | 2.377 | 1.425 | 465 | 0 |
| Current Assets | 26.749 | 42.397 | 83.739 | 179.597 | 242.882 | 29.716 | 9.652 | 3.909 | 1.159 | 1.133 |
| Inventories | 15.590 | 17.415 | 8.702 | 168.320 | 80.220 | 19.358 | 0 | 0 | 0 | 0 |
| Receivables | 8.703 | 20.204 | 1.411 | 3.215 | 13.621 | 1.683 | 118 | 463 | 1.112 | 1.133 |
| Cash | 2.456 | 4.777 | 73.626 | 8.061 | 149.041 | 8.675 | 9.534 | 3.447 | 48 | 0 |
| Shareholders Funds | -13.847 | -2.630 | 75.393 | 130.673 | 259.482 | 38.607 | 9.352 | 5.333 | 533 | -1.307 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 75.081 | 62.855 | 20.250 | 115.385 | 9.820 | 5.312 | 2.676 | 0 | 1.091 | 2.440 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4690 - 4690" | |||||||||
| CAEN Financial Year |
4690
|
|||||||||
Comments - Grandpharma Srl